Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | VDR | P11473 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6777669 | 0.80 | PIK3CD (0.42) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL6481556 | 0.78 | — | — | |
| SCHEMBL20841814 | 0.74 | NAMPT (0.41) | SMN1; SMN2ALDH1A1MEN1CYP2C19KMT2A | |
| SCHEMBL8536193 | 0.74 | — | — | |
| SCHEMBL15606268 | 0.74 | — | — | |
| SCHEMBL6779927 | 0.73 | MGLL (0.50) | ALDH1A1HTT | |
| SCHEMBL179104 | 0.73 | — | — | |
| SCHEMBL24300568 | 0.72 | MGLL (0.48) | SMN1; SMN2ALDH1A1HTT | |
| SCHEMBL2905468 | 0.72 | MGLL (0.53) | SMN1; SMN2ALDH1A1CYP2C19HTT | |
| SCHEMBL23132249 | 0.72 | ALDH1A1 (0.32) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140369992-A1 | C-Terminally Tethered Amino Acids and Their Fibrinolytic Therapeutic Uses | CANADIAN BLOOD SERVICES (CA) | 2014-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140369992-A1 | C-Terminally Tethered Amino Acids and Their Fibrinolytic Therapeutic Uses | HABP2, FGB, PROC | SMN1; SMN2 4220/4885ALDH1A1 4658/4885SORT1 1026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.